IMMUNOPATHOGENESIS OF LP-BM5 INFECTION-MURINE ACQUIRED IMMUNODEFICIENCY DISEASE
LP-BM5感染鼠获得性免疫缺陷病的免疫发病机制
基本信息
- 批准号:3770384
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:B lymphocyte MHC class I antigen MHC class II antigen Retroviridae Retroviridae disease acquired immunodeficiency cell population study disease /disorder model genetic strain graft versus host disease immunopathology laboratory mouse liposomes macrophage polymerase chain reaction provirus skin virus infection mechanism
项目摘要
Studies have been undertaken to evaluate the immunopathogenesis of MAIDS,
a murine immunodeficiency disease produced by infection with a mixture of
LP-BM5 retroviruses. Specifically we are assessing 1) the response to
infection by susceptible and resistant lymphoid populations, 2) the
contribution of allospecific responses to generation of disease, 3) the
contribution to infection of non-lymphoid host target tissues, and 4) the
role of macrophages in induction and maintenance of infection.
1) Susceptible B6 mice develop MAIDS within 8 weeks of infection whereas
resistant 129 strain mice do not develop infection in over 8 months. To
test whether resistant cells could modify the course of infection in
susceptible animals, we infected B6<->129 allophenic mice, whose lymphoid
compartments were chimeric in that they contained cells of B6
(susceptible) origin and cells of 129 (resistant) origin, with LP-BM5.
Surprisingly, these animals developed accelerated lymphadenopathy and
splenomegaly relative to control B6 mice, indicating that the presence of
resistant cells was not sufficient to suppress infection. However, this
occurred in animals in which only a maximum of 35% of the lymphoid
compartment was composed of resistant cells. Experiments are in progress
to assess whether infection can be modulated when the percentage of
resistant cells is higher.
2) Retroviruses initiate disease by inoculation either as a cell free
extract or in a cell associated form. In the case of HIV infection,
presentation of cell associated virus transpires across allogeneic
histocompatibility barriers. To understand the role of such effects, mice
were inoculated with cell associated LP-BM5 retroviruses across MHC class
I or MHC class II histocompatibility barriers and assessed for infection.
Preliminary results reveal that relative to control syngeneically infected
mice, accelerated disease was observed across MHC class II barriers and
attenuated disease across MHC class I barriers. That this did not merely
reflect differential susceptibilities of different strains to viral
infection was shown by an equivalent rate of disease development in the
three strains on inoculation of cell free virus. Further studies are
being done to confirm these observations and to explore the mechanisms by
which such effects are mediated.
3) It has been demonstrated that the course of MAIDS infection is
dramatically attenuated by chemotherapy that obliterates the lymphoid and
bone marrow compartments. Nonetheless, disease recrudesces following
repletion of lymphoid cells indicating that other tissues may harbor LP-
BM-85 virus and prove a source of reinfection. Previous studies indicate
that skin cell populations may harbor LP-BM5 virus because disease may be
transmitted via skin grafts from infected animals. We have found evidence
by PCR analysis of provirus in skin samples of infected but no non-
infected mice. Studies are underway to specifically identify which skin
cells may harbor infective virus.
4) The role of the macrophage in generation of MAIDS from LP-BM5
infection is not clear. To assess contributions of the macrophage to
disease generation, we are specifically depleting macrophages by injection
of toxic liposomes into mice inoculated with LP-BM5.
已经进行了研究来评估MAIDS的免疫发病机制,
一种鼠免疫缺陷病,由感染
LP-BM 5逆转录病毒。 具体而言,我们正在评估1)对以下问题的反应:
易感和耐药淋巴群体的感染,2)
同种异体反应对疾病产生的贡献,3)
对非淋巴宿主靶组织感染的贡献,以及4)
巨噬细胞在诱导和维持感染中的作用。
1)易感B6小鼠在感染后8周内发生MAIDS,
抗性129品系小鼠在超过8个月内不发生感染。 到
测试耐药细胞是否可以改变感染过程,
易感动物,我们感染了B6 <->129同种异体小鼠,其淋巴
隔室是嵌合的,因为它们含有B6细胞
(敏感)来源的细胞和129(抗性)来源的细胞,具有LP-BM 5。
令人惊讶的是,这些动物出现了加速的淋巴结病,
相对于对照B6小鼠脾肿大,表明存在
抗性细胞不足以抑制感染。 但这
发生在只有最多35%的淋巴细胞
隔室由抗性细胞组成。 实验正在进行
以评估感染是否可以被调制时,
抗性细胞更高。
2)逆转录病毒通过接种或作为无细胞接种来引发疾病。
提取物或以细胞相关的形式。在艾滋病毒感染的情况下,
细胞相关病毒的呈递在同种异体
组织相容性屏障 为了了解这种效应的作用,小鼠
接种细胞相关的LP-BM 5逆转录病毒,
I或MHC II类组织相容性屏障,并评估感染。
初步结果显示,相对于同基因感染的对照,
在小鼠中,观察到加速的疾病跨越MHC II类屏障,
通过MHC I类屏障减弱疾病。 这不仅仅是
反映不同毒株对病毒的不同亲和性
感染表现为疾病发展的相同速率,
接种无细胞病毒的三株。 进一步的研究
正在做的工作,以确认这些意见,并探讨机制,
这种影响是由哪些因素引起的。
3)已经证明MAIDS感染的过程是
通过化学疗法显著减弱,
骨髓腔 尽管如此,疾病在以下情况下复发
淋巴细胞的充盈表明其他组织可能含有LP-
BM-85病毒并证明是再感染的来源。 先前的研究表明
皮肤细胞群可能携带LP-BM 5病毒,因为疾病可能是
通过受感染动物的皮肤移植传播。 我们发现了证据
通过PCR分析感染者皮肤样本中的前病毒,
感染的老鼠 研究正在进行中,以具体确定哪种皮肤
细胞可能携带感染性病毒。
4)巨噬细胞在LP-BM 5产生MAIDS中的作用
感染尚不清楚。 为了评估巨噬细胞对
疾病的产生,我们专门通过注射消耗巨噬细胞
将毒性脂质体注射到接种LP-BM 5的小鼠中。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A S ROSENBERG其他文献
A S ROSENBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A S ROSENBERG', 18)}}的其他基金
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVIRALLY RESISTANT CELLS
评估逆转录病毒抗性细胞安全性的临床前动物模型
- 批准号:
6161320 - 财政年份:
- 资助金额:
-- - 项目类别:
CELLULAR POPULATIONS MEDIATING SKIN ALLOGRAFT REJECTION
介导皮肤同种异体移植排斥的细胞群
- 批准号:
3770383 - 财政年份:
- 资助金额:
-- - 项目类别:
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVIRALLY RESISTANT CELLS
评估逆转录病毒抗性细胞安全性的临床前动物模型
- 批准号:
5200785 - 财政年份:
- 资助金额:
-- - 项目类别:
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVI
用于评估 RETROVI 安全性的临床前动物模型
- 批准号:
6547391 - 财政年份:
- 资助金额:
-- - 项目类别:
PRECLINICAL ANIMAL MODEL TO ASSESS THE SAFETY OF RETROVIRALLY RESISTANT CELLS
评估逆转录病毒抗性细胞安全性的临床前动物模型
- 批准号:
2569000 - 财政年份:
- 资助金额:
-- - 项目类别:
IMMUNOPATHOGENESIS OF LP-BM5 INFECTION-MURINE ACQUIRED IMMUNODEFICIENCY DISEASE
LP-BM5感染鼠获得性免疫缺陷病的免疫发病机制
- 批准号:
3748227 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Elucidating a molecular understanding of ILC2 MHC class I antigen cross priming
阐明 ILC2 MHC I 类抗原交叉引发的分子理解
- 批准号:
486527 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship Programs
Restoring MHC class I antigen presentation to enhance anti-tumour immunity
恢复MHC I类抗原呈递,增强抗肿瘤免疫力
- 批准号:
nhmrc : GNT1164054 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Project Grants
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
- 批准号:
8996707 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Ubiquitin conjugation and direct MHC class I antigen presentation
泛素结合和直接 MHC I 类抗原呈递
- 批准号:
8880646 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
- 批准号:
9206412 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
- 批准号:
8723605 - 财政年份:2014
- 资助金额:
-- - 项目类别:
MHC Class I Antigen Presentation in Viral Infections
病毒感染中 MHC I 类抗原呈递
- 批准号:
8072956 - 财政年份:2010
- 资助金额:
-- - 项目类别:
The function of the Ubiquitin-Proteasome-System (UPS) in MHC class I antigen processing in target cells and maturing human dendritic cells (hDCs).
泛素蛋白酶体系统 (UPS) 在靶细胞和成熟人树突细胞 (hDC) 中 MHC I 类抗原加工中的功能。
- 批准号:
105348415 - 财政年份:2009
- 资助金额:
-- - 项目类别:
Research Grants
In vivo analysis of the imnportance of proteasome immunosubunits and of PA28 for MHC class I antigen processing, CTL response induction and tumor-virus elimination (A 7)
体内分析蛋白酶体免疫亚基和 PA28 对于 MHC I 类抗原加工、CTL 反应诱导和肿瘤病毒消除的重要性 (A 7)
- 批准号:
5354871 - 财政年份:2002
- 资助金额:
-- - 项目类别:
Collaborative Research Centres
MHC Class I Antigen Presentation in Viral Infections
病毒感染中 MHC I 类抗原呈递
- 批准号:
7991835 - 财政年份:2001
- 资助金额:
-- - 项目类别:














{{item.name}}会员




